Considering that colorectal NECs harbour more BRAF mutations than do other types of CRC, it is critical to perform molecular testing for BRAF in patients with colorectal NEC to optimize patient selection for promising therapeutic options, such as BRAF inhibitors. This evidence concerns the gene BRAF and colorectal carcinoma.